These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7627705)

  • 21. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
    Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue factor pathway inhibitor (TFPI)--an update.
    Sandset PM
    Haemostasis; 1996 Oct; 26 Suppl 4():154-65. PubMed ID: 8979119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue factor pathway inhibitor: a possible mechanism of action.
    Panteleev MA; Zarnitsina VI; Ataullakhanov FI
    Eur J Biochem; 2002 Apr; 269(8):2016-31. PubMed ID: 11985578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation.
    Golino P; Ragni M; Cimmino G; Forte L
    Cardiovasc Drug Rev; 2002; 20(1):67-80. PubMed ID: 12070535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
    Lockett JM; Mast AE
    Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
    Mast AE; Stadanlick JE; Lockett JM; Dietzen DJ; Hasty KA; Hall CL
    J Biol Chem; 2000 Oct; 275(41):31715-21. PubMed ID: 10922378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
    Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
    J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and functional properties of apolipoprotein B in chemically modified low density lipoproteins.
    Vanderyse L; Devreese AM; Baert J; Vanloo B; Lins L; Ruysschaert JM; Rosseneu M
    Atherosclerosis; 1992 Dec; 97(2-3):187-99. PubMed ID: 1466663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo.
    Gouin-Thibault I; Dewar L; Craven S; Kulczycky M; Wun TC; Ofosu FA
    Br J Haematol; 1996 Dec; 95(4):738-46. PubMed ID: 8982054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
    Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
    Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
    Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.
    Sevinsky JR; Rao LV; Ruf W
    J Cell Biol; 1996 Apr; 133(2):293-304. PubMed ID: 8609163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro.
    Mougenot N; Lesnik P; Ramirez-Gil JF; Nataf P; Diczfalusy U; Chapman MJ; Lechat P
    Atherosclerosis; 1997 Sep; 133(2):183-92. PubMed ID: 9298678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
    Li A; Chang AC; Peer GT; Wun TC; Taylor FB
    Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative modification of LDL: comparison between cell-mediated and copper-mediated modification.
    Parthasarathy S; Fong LG; Quinn MT; Steinberg D
    Eur Heart J; 1990 Aug; 11 Suppl E():83-7. PubMed ID: 2121485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway.
    McNally AK; Chisolm GM; Morel DW; Cathcart MK
    J Immunol; 1990 Jul; 145(1):254-9. PubMed ID: 2162888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
    Hackeng TM; Seré KM; Tans G; Rosing J
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complementary DNA sequencing of canine tissue factor pathway inhibitor reveals a unique nanomeric repetitive sequence between the second and third Kunitz domains.
    Girard TJ; Gailani D; Broze GJ
    Biochem J; 1994 Nov; 303 ( Pt 3)(Pt 3):923-8. PubMed ID: 7980463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of endothelial cells and their products in the modification of low-density lipoproteins.
    van Hinsbergh VW; Scheffer M; Havekes L; Kempen HJ
    Biochim Biophys Acta; 1986 Aug; 878(1):49-64. PubMed ID: 3730414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.